Bank of The West Reduces Position in Becton, Dickinson and Company (NYSE:BDX)

Bank of The West cut its stake in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 2.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,784 shares of the medical instruments supplier’s stock after selling 216 shares during the period. Bank of The West’s holdings in Becton, Dickinson and were worth $2,869,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Accel Wealth Management increased its position in shares of Becton, Dickinson and by 100.0% during the fourth quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 50 shares during the period. Sierra Capital LLC increased its position in shares of Becton, Dickinson and by 88.7% in the fourth quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. Level Financial Advisors Inc. bought a new position in shares of Becton, Dickinson and in the fourth quarter worth approximately $26,000. Icapital Wealth LLC bought a new position in shares of Becton, Dickinson and in the first quarter worth approximately $31,000. Finally, Disciplined Investments LLC bought a new position in shares of Becton, Dickinson and in the first quarter worth approximately $32,000. Hedge funds and other institutional investors own 86.58% of the company’s stock.

In other Becton, Dickinson and news, VP Thomas J. Spoerel sold 443 shares of the stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $260.00, for a total value of $115,180.00. Following the completion of the transaction, the vice president now owns 1,058 shares in the company, valued at $275,080. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP David Hickey sold 475 shares of the stock in a transaction on Friday, May 6th. The stock was sold at an average price of $256.00, for a total value of $121,600.00. Following the completion of the transaction, the executive vice president now owns 3,806 shares of the company’s stock, valued at approximately $974,336. The disclosure for this sale can be found here. 0.50% of the stock is currently owned by corporate insiders.

Shares of BDX stock opened at $251.80 on Tuesday. The stock has a fifty day moving average of $249.66 and a 200 day moving average of $258.24. Becton, Dickinson and Company has a 52 week low of $231.46 and a 52 week high of $280.62. The firm has a market capitalization of $71.78 billion, a price-to-earnings ratio of 39.72, a PEG ratio of 3.39 and a beta of 0.62. The company has a quick ratio of 1.04, a current ratio of 1.52 and a debt-to-equity ratio of 0.72.

Becton, Dickinson and (NYSE:BDXGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.20. The business had revenue of $5.01 billion during the quarter, compared to the consensus estimate of $4.78 billion. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.19 earnings per share. Equities research analysts anticipate that Becton, Dickinson and Company will post 11.21 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 30th. Shareholders of record on Thursday, June 9th were issued a $0.87 dividend. The ex-dividend date was Wednesday, June 8th. This represents a $3.48 dividend on an annualized basis and a yield of 1.38%. Becton, Dickinson and’s dividend payout ratio (DPR) is 54.89%.

Several analysts have issued reports on the company. StockNews.com lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Saturday. Morgan Stanley increased their price objective on Becton, Dickinson and from $293.00 to $295.00 and gave the company an “overweight” rating in a research note on Monday, April 11th. Wells Fargo & Company raised Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price objective for the company in a research note on Friday, June 24th. Finally, Piper Sandler dropped their price objective on Becton, Dickinson and from $265.00 to $255.00 in a research note on Thursday, May 5th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Becton, Dickinson and presently has a consensus rating of “Hold” and a consensus target price of $279.17.

Becton, Dickinson and Company Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Read More

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.